Skip to main content
SpringerLink
Log in

Head and neck cancer

Docetaxel-based CRT improves survival in cisplatin-ineligible patients

  • Research Highlight
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

  • 7 Altmetric

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Docetaxel-based CRT improves survival in cisplatin-ineligible patients. Nat Rev Clin Oncol 20, 210 (2023). https://doi.org/10.1038/s41571-023-00740-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00740-7

  • Springer Nature Limited

Search

Navigation